|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Stanley, SA, Kawate, T, Iwase, N, Shimizu, M, Clatworthy, AE, Kazyanskaya, E, Sacchettini, JC, Ioerger, TR, Siddiqi, NA, Minami, S, Aquadro, JA, Schmidt Grant, S, Rubin, EJ, Hung, DT|
|Journal||Proceedings of the National Academy of Sciences of the United States of America|
Infection with the bacterial pathogen Mycobacterium tuberculosis imposes an enormous burden on global public health. New antibiotics are urgently needed to combat the global tuberculosis pandemic; however, the development of new small molecules is hindered by a lack of validated drug targets. Here, we describe the identification of a 4,6-diaryl-5,7-dimethyl coumarin series that kills M. tuberculosis by inhibiting fatty acid degradation protein D32 (FadD32), an enzyme that is required for biosynthesis of cell-wall mycolic acids. These substituted coumarin inhibitors directly inhibit the acyl-acyl carrier protein synthetase activity of FadD32. They effectively block bacterial replication both in vitro and in animal models of tuberculosis, validating FadD32 as a target for antibiotic development that works in the same pathway as the established antibiotic isoniazid. Targeting new steps in well-validated biosynthetic pathways in antitubercular therapy is a powerful strategy that removes much of the usual uncertainty surrounding new targets and in vivo clinical efficacy, while circumventing existing resistance to established targets.